Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

The commodities, which were flagged off by Health Cabinet Secretary Deborah Barasa on Friday, March 14, include ARV drugs ...